Insights into the Pathobiology of Secondary AML

Tania Jain, Raajit K. Rampal

Research output: Chapter in Book/Report/Conference proceedingChapter


Secondary acute myeloid leukemia (s-AML) is recognized as AML arising from prior hematological disease, usually myelodysplastic syndrome, myeloproliferative neoplasm, or aplastic anemia or has myelodysplasia related changes or develops in context of prior cytotoxic or radiation therapy. Understanding the biology of s-AML is of utmost importance as this portends a high-risk disease including a potential for lower responses to chemotherapy. Some therapeutic developments in recent times have been CPX-351 as well as venetoclax-containing combinations. Of particular ongoing and forthcoming interest is the role of targeted therapy itself or in combination with other agents. Lastly, the role of allogeneic stem cell transplantation remains crucial although debated, and with improvement in treatment strategies provides opportunities to use the two in combination for best results.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Number of pages12
StatePublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774


  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Myeloproliferative neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Insights into the Pathobiology of Secondary AML'. Together they form a unique fingerprint.

Cite this